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Pancreatic cancer is among the leading causes of cancer-related
death worldwide (National Cancer Institute, 1991), and the diag-
nosis is established at an advanced stage in the majority of patients
who are, therefore, beyond the scope of curative intervention
(American Cancer Society, 1991; Warshaw and Fernandez-del
Castillo, 1992). Although a positive impact of chemotherapeutic
intervention upon survival and quality of life in cancer of the
exocrine pancreas has been reported (Glimelius et al, 1996),
chemotherapy is usually limited to patients with a good perfor-
mance status and normal liver and renal functions.
According to recent data (Cascinu et al, 1995), the application
of somatostatin (SST) analogues seems to prolong survival in
patients suffering from various gastrointestinal cancers. Among
the patients randomized between treatment with the SST analogue
octreotide (OCT) and best supportive care, there was a high
percentage of subjects with pancreatic cancer, who demonstrated a
statistically significant benefit in terms of survival compared with
untreated controls. Apart from OCT, other long-acting SST
analogues have been synthesized and investigated in vitro and in
vivo (Anthony et al, 1993; Kuhn et al, 1994). Lanreotide (LAN)
has been evaluated for the treatment of acromegalic patients
(Caron et al, 1993; Marek et al, 1994) and has been found to be
well tolerated and biologically active when administered by intra-
muscular injection in a slow-release formulation, necessitating
reinjection of the peptide at intervals of only 10—14 days.
Taken together, these findings prompted us to investigate the
therapeutic potential of LAN for treatment of advanced pancreatic
cancer. In addition, we have also investigated in vivo targeting of
SST receptors by means of [111In]DTPA-D-Phe1-OCT scintigraphy
([111In]OCT), which is being used for imaging of neuroendocrine
malignancies (Krenning et al, 1993). This was accompanied by
experiments to further define in vitro SSTR expression and
binding of SST analogues to human tumour specimens.
PATIENTS AND METHODS
Fourteen untreated patients (eight women/six men) with a median
age of 55 years (range 41—75 years) were enrolled in this trial. The
median WHO performance status was 1 (range 0—2), and nine
patients had documented weight loss exceeding 5 kg before initia-
tion of therapy. All patients gave informed consent according to
institutional guidelines. All patients had histologically verified
metastatic cancer of the pancreas with at least one bidimensionally
measurable target lesion as seen on computerized tomography
(CT) not older than 4 weeks upon study entry. Twelve patients had
liver metastases, and two had lymph node metastases. Patients
with severe concomitant illness or disease metastatic to the CNS
were excluded from the trial. Serial CT scanning and evaluation of
tumour markers were performed every 8 weeks. In addition, the
patients￿ performance status, weight and intake of analgesic
medication as well as subjective perception of pain using a visual
analogue scale were recorded before the start of treatment and
before each injection of LAN.
For treatment of patients included in this study, the slow-release
formulation of LAN (Somatuline LP 30-mg vials, Ipsen Biotech,
Paris, France) was used, given by deep intramuscular injection
every 10 days until documented progression or the patients￿ wish
to withdraw from the study. The minimal time span between OCT
scanning and the first injection of LAN had to be at least 14 days.
All patients underwent scanning by means of 111In-labelled
OCT, using the commercially available preparation (OctreoScan,
Mallinckrodt Medical, UK). For imaging purposes, 10 mg DTPA-
D-Phe1-OCT were labelled with 120—150 MBq of 111InCl3,
according to the manufacturer￿s description. Patients were given
the tracer by intravenous bolus injection before initiation of
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Vienna, Austriatherapy, and scanning was performed according to published stan-
dard methods (Krenning et al, 1993).
Human tumour samples
Pancreatic cancer cells cultivated from ascitic fluid (n = 3) and
primary pancreatic adenocarcinomas (n = 5) or obtained during
surgery (n = 3) or autopsy (n = 2) were investigated for the pres-
ence of SSTR2 mRNA by means of Northern blotting. In addition,
binding studies using both 111In-labelled OCT and LAN according
to published methods (Scatchard, 1949; Virgoloni et al, 1994)
were carried out in tumour samples and short-term cultures
obtained from ascitic fluid.
RESULTS
All patients entered in the study received treatment with LAN as
scheduled. A median number of eight injections were adminis-
tered (range 5—14); four patients had stable disease (SD) lasting
between 3.5 and >6 months, whereas the remaining ten patients
progressed during treatment.
Four patients showed a reduction in CA19-9 values by more
than 30% for 4—16 weeks, and two of these patients also displayed
an improvement in WHO performance status lasting for 8 and 10
weeks respectively. No beneficial influence of treatment on body
weight could be demonstrated, and the intake of analgesic medica-
tion as well as subjective perception of pain did not improve
compared with baseline evaluations.
At the time of this evaluation, all patients have died except one,
who is alive with ongoing stable disease 6 months after initiation
of therapy. The median time to progression was 2.0 months (range
1.5—6.0 months) and the median survival was 4.0 months (range
1.8—7.0 months).
No severe side-effects necessitating discontinuation of treat-
ment were experienced by our patients, and only four patients had
mild gastrointestinal complaints consisting of meteorism accom-
panied by mild diarrhoea in three patients and mild nausea in two.
One additional patient developed discrete swelling and erythema
at the injection site.
All 14 patients underwent scanning with [111In]OCT before initi-
ation of LAN treatment. No focal tracer uptake corresponding to
tumour sites could be demonstrated in primary tumours, lymph
nodes or liver metastases by means of [111In]OCT. Northern blot-
ting did not demonstrate the presence of mRNA specific for SSTR2
in human samples, and no significant binding of both [111In]OCT
and [111I]LAN to tumour samples could be demonstrated.
DISCUSSION
Despite the recent demonstration of a positive influence of
chemotherapy on survival and quality of life in patients with
pancreatic cancer (Glimelius et al, 1996), the overall prognosis for
individuals with advanced disease remains dismal. As a result of
the limited efficacy of treatment, there is continuing interest in
attempts to identify new therapeutic options. Based on in vitro data
suggesting the potential of SST analogues to provide an anti-
mitogenic stimulus in various tumour models (Qin et al, 1992;
Weckbecker et al, 1992; Reubi et al, 1994), Cascinu et al (1995)
have reported a beneficial impact of treatment with OCT in patients
with advanced pancreatic cancer. In addition, a therapeutic benefit
for patients treated with high-dose OCT (Ebert et al, 1994) was
reported in another study, implicating SST analogues as potential
tools for treatment of advanced pancreatic cancer.
In this study, we have investigated the application of the long-
acting SST analogue LAN in patients with pancreatic cancer.
In contrast to OCT, which has a serum half-life of approximately
100 min after subcutaneous injection (Bauer et al, 1982), LAN has
been demonstrated to be biologically active and well tolerated
when given as a slow-release formulation (Marek et al, 1994;
Caron et al, 1995) every 10—14 days at the dose applied in our
series. Therapeutic results in our study, however, were disap-
pointing: four patients had SD lasting between 3.5 and 6 months,
whereas the remaining patients rapidly progressed. The median
survival was 4 months, and a short improvement in performance
status could be demonstrated in only two patients. Analgesic
intake, subjective pain perception and body weight were not bene-
ficially influenced in our patients. These results are consistent with
phase II data reported with the use of OCT, in which median
survivals between 2 and 6 months have been observed (Kiljn et al,
1990; Canobbio et al, 1992; Hughier et al, 1992; Ebert et al, 1994).
In contrast, Cascinu et al (1995) reported a significantly prolonged
survival in patients suffering from pancreatic cancer with the
administration of OCT, with the median survival being 15 weeks
compared with 7 weeks in untreated patients. Although the
survival time of treated patients seems to be comparable with our
data and other trials reported (Kiljn et al, 1990; Canobbio et al,
1992; Hughier et al, 1992; Ebert et al, 1994), the survival in the
control cohort appears to be exceptionally short, offering a
plausible explanation for the statistically significant difference.
Because of conflicting in vitro and in vivo data with regard to
SST receptor expression and growth inhibition in various cancers
(Reubi et al, 1988, 1990; Janson et al, 1996), we have attempted
to define the in vivo receptor status of our patients by means of
[111In]DTPA-D-Phe1-OCT, which is widely applied for detection
and staging of neuroendocrine tumours (Krenning et al, 1993).
Scintigraphy was performed before application of LAN to avoid a
potential influence on receptors after prolonged peptide adminis-
tration, and thus to prevent false scan results. Both OCT and LAN
have been reported to bind to at least one of the same SST receptor
subtypes with high affinity, namely SSTR2 (Viollet et al, 1995;
Janson et al, 1996). In our patients, no positive [111In]OCT scans
could be obtained, indicating the absence of clinically relevant
amounts of SSTR2. This is in accordance with data obtained in our
tumour samples and with results published by various groups
(Reubi et al, 1988; Krenning et al, 1993; Taylor et al, 1994;
Buscail et al, 1996), indicating the loss of expression of SSTR2 in
pancreatic cancer. Because this receptor subtype seems to play a
crucial role in the growth inhibition attributed to SST analogues,
the absence of SSTR2 offers the most likely explanation for the
disappointing therapeutic results. Taken together, our results add
to the accumulating body of evidence that SST analogues do not
seem to result in convincing palliation or prolongation of survival
in advanced pancreatic cancer.
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